Tumor Metabolism
肿瘤代谢
基本信息
- 批准号:10391399
- 负责人:
- 金额:$ 0.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-03 至 2022-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAntimetabolitesBackCanadaCancer BiologyCellsClinicalCollaborationsDataDependenceDevelopmentEducational workshopFutureImmuneImmune responseImmunotherapyIndustrializationInvadedKnowledgeLymphocyteMalignant NeoplasmsMentorsMetabolicMetabolismMethodologyObesityOncogenesOutcomeOvernutritionPathway interactionsPositron-Emission TomographyProliferatingResearchResearch PersonnelScientistSeminalSignal TransductionTechnologyTherapeuticTherapeutic InterventionWarburg EffectWorkanti-cancercancer cellchemotherapeutic agentclinical practiceclinical translationdesigndrug metabolismfluorodeoxyglucose positron emission tomographyin vivointerestmeetingsmetabolic abnormality assessmentmicrobiomepostersprospectivesuccesssupport networksymposiumtumortumor metabolismtumor microenvironment
项目摘要
ABSTRACT
Support is requested for a Keystone Symposia conference entitled Tumor Metabolism, organized by Drs.
Eileen P. White, Joshua D. Rabinowitz, Marcia C. Haigis and David M. Sabatini. The conference is anticipated
to be held in Banff, Canada from February 6-10, 2022.
The field of tumor metabolism is one of the oldest in cancer biology, dating back to the seminal work of Otto
Warburg in the 1920s. Clinical importance of tumor metabolism is well validated by the successes both of
FDG-PET imaging and of antimetabolites as chemotherapeutic agents. The recognition that oncogenes both
promote the Warburg effect and activate anabolic pathways has provided impetus for revitalized examination
of tumor metabolism. This conference brings together leaders in tumor metabolism to discuss ongoing efforts
to understand and target metabolism of proliferating cancer cells and their support network. This conference
will address key questions regarding the metabolism of proliferating cells, the unique metabolic features of
tumors in vivo, and the associated opportunities for therapeutic intervention, including at the interface between
metabolism and immunotherapy. Key scientific questions that conference session will cover include (1) which
features of cancer cell metabolism are shared across proliferating cells, and which are cancer specific? (2) how
does signaling drive metabolism, and how does metabolism impact signaling and cell fate decisions? and (3)
what are the dependencies of tumors on host metabolism, and what is the impact of tumor metabolism on host
cells, including invading lymphocytes? By holding this meeting jointly with the Keystone meeting on
“Immunometabolism at the Crossroads of Obesity and Cancer” we aim to synergistically address how
overnutrition, the microbiome, and the metabolism of immune cells in the tumor microenvironment influences
that anti-cancer immune response. Through discussion of these and other questions, the conference aims to
generate new scientific ideas, promote collaborations, and enhance dissemination of the latest technologies
and best practices for metabolic studies. As the premier venue sharing important unpublished data in the tumor
metabolism field, this conference will help to accelerate scientific discovery and the development of new
strategies to treat cancer.
摘要
请求支持由博士组织的题为肿瘤代谢的Keystone研讨会。
题名/责任者:The First of the First,and and the First of the First.这次会议令人期待。
将于2022年2月6日至10日在加拿大班夫举行。
肿瘤代谢领域是癌症生物学中最古老的领域之一,可以追溯到奥托的开创性工作。
20世纪20年代的华堡。两项研究的成功充分证明了肿瘤代谢的临床重要性。
FDG-PET成像和抗代谢药物作为化疗药物的研究。认识到癌基因既有
推动华宝效应,激活合成代谢通路,为振兴考试提供了动力
肿瘤的新陈代谢。这次会议汇聚了肿瘤新陈代谢领域的领袖,讨论正在进行的努力。
了解和靶向增殖癌细胞及其支持网络的新陈代谢。这次会议
将解决有关增殖细胞新陈代谢的关键问题,即
体内肿瘤,以及相关的治疗干预机会,包括在
新陈代谢和免疫治疗。会议将讨论的关键科学问题包括(1)
癌细胞代谢的特征在增殖细胞中是相同的,哪些是癌症特有的?(2)如何
信号是否驱动新陈代谢,新陈代谢如何影响信号和细胞命运的决定?和(3)
肿瘤对宿主代谢的依赖性是什么,肿瘤代谢对宿主的影响是什么
细胞,包括入侵的淋巴细胞?通过与Keystone会议联合举行这次会议
“肥胖和癌症的十字路口的免疫新陈代谢”我们的目标是协同解决
肿瘤微环境中的营养过剩、微生物群和免疫细胞的新陈代谢都会影响
抗癌免疫反应。通过对这些问题和其他问题的讨论,会议旨在
产生新的科学思想,促进合作,加强最新技术的传播
和代谢研究的最佳实践。作为共享肿瘤中重要的未发表数据的首要场所
新陈代谢领域,这次会议将有助于加快科学发现和新技术的发展
治疗癌症的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thale Cross Jarvis其他文献
Thale Cross Jarvis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thale Cross Jarvis', 18)}}的其他基金
Autophagy and Neurodegeneration: Mechanisms to Therapies
自噬和神经退行性变:治疗机制
- 批准号:
10608666 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Malaria: Confronting Challenges From Drug Discovery to Treatment
疟疾:面临从药物发现到治疗的挑战
- 批准号:
10468493 - 财政年份:2022
- 资助金额:
$ 0.5万 - 项目类别:
Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics
现代表型药物发现:从化学生物学到治疗学
- 批准号:
10468419 - 财政年份:2022
- 资助金额:
$ 0.5万 - 项目类别:
相似海外基金
Antimetabolites Effective against Resistant Gram-positive Bacteria
抗代谢药可有效对抗耐药革兰氏阳性细菌
- 批准号:
8705774 - 财政年份:2014
- 资助金额:
$ 0.5万 - 项目类别:
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
一线抗代谢药物作为类固醇节约治疗 (FAST) 葡萄膜炎试验
- 批准号:
8549253 - 财政年份:2012
- 资助金额:
$ 0.5万 - 项目类别:
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
一线抗代谢药物作为类固醇节约治疗 (FAST) 葡萄膜炎试验
- 批准号:
8724947 - 财政年份:2012
- 资助金额:
$ 0.5万 - 项目类别:
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
一线抗代谢药物作为类固醇节约治疗 (FAST) 葡萄膜炎试验
- 批准号:
8266928 - 财政年份:2012
- 资助金额:
$ 0.5万 - 项目类别: